Though AAco-AlbiVax only delivered three MHC-I-restricted antigens expected to elicit CD8+ T cells, the ability of radioimmunotherapy to elicit CD4+ T cell responses is likely due to the generation of endogenous MHC-II-restricted tumor antigens by radiation and the bystander effect of radioimmunotherapy. Here, CD4 is linked to neoplasm.